Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.168,82
0,44%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Phio Pharmaceuticals Corporation (PHIO) Phio Pharmaceuticals Corporation (PHIO) Notizie

Phio Pharmaceuticals Corporation

PHIO
0,88
0,1043 (13,45%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202413:30GLOBEPhio Pharmaceuticals Announces Upcoming Presentation at the..
22/4/202419:10GLOBEIntratumoral Injection of Phio’s PH-762 significantly..
16/4/202413:30GLOBEPhio Pharmaceuticals Announces Upcoming Presentations at the..
11/4/202413:30GLOBEPhio Pharmaceuticals Announces Upcoming Presentation at the..
03/4/202413:30GLOBENational Spotlight Features Phio’s Innovative RNAi..
02/4/202413:30GLOBEPhio Pharmaceuticals Reports 2023 Year End Financial Results..
21/3/202412:30GLOBEPhio Pharmaceuticals Presenting Data Showing INTASYL May..
13/3/202419:00GLOBEPhio Pharmaceuticals Announces Addition of Clinical Trial..
06/3/202416:30GLOBEPhio Pharmaceuticals Announces Patent Granted by USPTO,..
06/3/202401:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202401:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202416:30EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202414:00GLOBEPhio Pharmaceuticals Announces Data Showing INTASYL May..
26/1/202423:00EDGAR2Form 8-K - Current report
28/12/202315:13EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
28/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
19/12/202322:52EDGAR2Form S-1 - General form for registration of securities under..
08/12/202323:00EDGAR2Form 8-K - Current report
07/12/202314:00GLOBEPhio Pharmaceuticals Announces Exercise of Warrants for $2.8..
09/11/202322:40EDGAR2Form 8-K - Current report
09/11/202322:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:30GLOBEPhio Pharmaceuticals Reports Third Quarter 2023 Financial..
09/11/202313:30GLOBEPhio Pharmaceuticals Announces First US Patient Enrolled in..
03/11/202317:00GLOBEPhio Pharmaceuticals Presents New Data Showing INTASYL..
12/10/202317:00GLOBEPhio Pharmaceuticals Announces Upcoming Presentation at the..
11/10/202313:30GLOBEPhio Pharmaceuticals Presents New Data for Targeting of BRD4..
06/9/202313:30GLOBEPhio CEO to Speak at Wainwright Conference in New York in..
21/8/202313:30GLOBEPhio Pharmaceuticals Announces Dosing of First Patient in..
21/8/202313:30EDGAR2Form 8-K - Current report
10/8/202322:40EDGAR2Form 8-K - Current report
10/8/202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:30GLOBEPhio Pharmaceuticals Reports Second Quarter 2023 Financial..
26/7/202322:30EDGAR2Form 8-K - Current report
Apertura: 0,81 Min: 0,7762 Max: 0,8299
Chiusura: 0,7757

La tua Cronologia

NASDAQ
PHIO
Phio Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network